Short radiation, immunotherapy, and chemo for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of rectal cancer called pMMR/MSS (this means your tumor doesn't have certain genetic changes).
- Your rectal tumor is low enough that it's below the peritoneal reflection (a landmark in the abdomen).
- Your cancer is locally advanced and has at least one high-risk feature, such as growing into nearby tissues, being in several lymph nodes, or being close to vital structures.
- You haven't had any prior cancer treatment (radiation, chemo, targeted therapy, or immunotherapy).
- You are in good general health (able to do daily activities) and your blood counts and organ function are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.